U.S. markets closed

Eloxx Pharmaceuticals, Inc. (ELOX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.1300+0.3020 (+7.89%)
At close: 04:00PM EST
4.4800 +0.35 (+8.47%)
After hours: 07:56PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.8280
Bid3.9800 x 1000
Ask4.2500 x 900
Day's Range3.4700 - 4.4000
52 Week Range0.1000 - 4.4000
Avg. Volume277,414
Market Cap357.89M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.8540
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ELOX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eloxx Pharmaceuticals, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

    ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time today, December 1, 2022, after close

  • GlobeNewswire

    Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

    Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells by the end of 2022 or early 2023 WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted gen

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

    Trial sites now open in Australia and the United KingdomWATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites for its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. “Rare diseases with nonsense mutations, such as Alport syndrome, are particularly challenging to treat. We are incredi